Abstract
A novel β-D-2′-deoxy-2′-α-fluoro-2′-β-C-(fluoromethyl)uridine phosphoramidate prodrug (1) has been synthesized. This compound exhibits submicromolar-level antiviral activity in vitro against HCV genotypes 1b, 1a, 2a, and S282T replicons (EC50 = 0.18–1.13 μM) with low cytotoxicity (CC50 > 1000 μM). Administered orally, prodrug 1 is well tolerated at doses of up to 4 g/kg in mice, and produces a high level of the corresponding triphosphate in rat liver.
| Original language | English |
|---|---|
| Pages (from-to) | 107-113 |
| Number of pages | 7 |
| Journal | European Journal of Medicinal Chemistry |
| Volume | 143 |
| DOIs | |
| State | Published - 1 Jan 2018 |
| Externally published | Yes |
Keywords
- 2′-α-fluoro-2′-β-C-(fluoromethyl)uridine
- Anti-HCV
- Phosphoramidate prodrug
- Triphosphate